JP2018504393A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504393A5
JP2018504393A5 JP2017534556A JP2017534556A JP2018504393A5 JP 2018504393 A5 JP2018504393 A5 JP 2018504393A5 JP 2017534556 A JP2017534556 A JP 2017534556A JP 2017534556 A JP2017534556 A JP 2017534556A JP 2018504393 A5 JP2018504393 A5 JP 2018504393A5
Authority
JP
Japan
Prior art keywords
compound
corresponding sulfonamide
unsubstituted
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017534556A
Other languages
English (en)
Japanese (ja)
Other versions
JP6683712B2 (ja
JP2018504393A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/098385 external-priority patent/WO2016101887A1/en
Publication of JP2018504393A publication Critical patent/JP2018504393A/ja
Publication of JP2018504393A5 publication Critical patent/JP2018504393A5/ja
Application granted granted Critical
Publication of JP6683712B2 publication Critical patent/JP6683712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017534556A 2014-12-24 2015-12-23 ネクローシス阻害薬 Active JP6683712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/094734 2014-12-24
CNPCT/CN2014/094734 2014-12-24
PCT/CN2015/098385 WO2016101887A1 (en) 2014-12-24 2015-12-23 Necrosis inhibitors

Publications (3)

Publication Number Publication Date
JP2018504393A JP2018504393A (ja) 2018-02-15
JP2018504393A5 true JP2018504393A5 (https=) 2019-01-31
JP6683712B2 JP6683712B2 (ja) 2020-04-22

Family

ID=56149285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017534556A Active JP6683712B2 (ja) 2014-12-24 2015-12-23 ネクローシス阻害薬

Country Status (9)

Country Link
US (3) US10092529B2 (https=)
EP (1) EP3224245B1 (https=)
JP (1) JP6683712B2 (https=)
KR (1) KR102596723B1 (https=)
CN (1) CN107108492B (https=)
AU (1) AU2015371824B2 (https=)
CA (1) CA2972294C (https=)
HK (1) HK1244792B (https=)
WO (1) WO2016101887A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3229807A4 (en) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibitors of cellular necrosis and related methods
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
MA44007A (fr) 2016-02-05 2018-12-19 Denali Therapeutics Inc Inhibiteurs du récepteur interagissant avec protéine kinase 1
CN105968068B (zh) * 2016-05-12 2018-08-03 太原理工大学 一种芳香亚硝基化合物与氮杂环丙烷化合物成环的方法
CN105949144B (zh) * 2016-05-12 2018-02-02 太原理工大学 芳香亚硝基化合物与氮杂环丙烷化合物成环的方法
TW201831464A (zh) * 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
HRP20220636T1 (hr) 2016-12-09 2022-07-22 Denali Therapeutics Inc. Spojevi korisni kao inhibitori ripk1
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EP3612223B1 (en) * 2017-04-17 2024-07-31 National Institute Of Biological Sciences, Beijing Treating male senescence
CA3063938A1 (en) 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods
US12048703B2 (en) * 2018-04-13 2024-07-30 University Of North Dakota Use of small molecule FAK activators to promote mucosal healing
US11512072B2 (en) 2018-04-19 2022-11-29 University Of Virginia Patent Foundation Compositions and methods for preparing and using azetidines
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
EP3883918B1 (en) 2018-11-20 2023-07-19 Sironax Ltd Rip1 inhibitors
SG11202105250TA (en) * 2018-11-20 2021-06-29 Sironax Ltd Cyclic Ureas
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
JP2023502514A (ja) 2019-11-26 2023-01-24 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 疾患の処置のための受容体相互作用プロテインキナーゼiの阻害剤
CA3183668A1 (en) * 2020-05-20 2021-11-25 Sironax Ltd. Azetidine cyclic ureas
CN115697991B (zh) 2020-05-20 2024-11-22 维泰瑞隆有限公司 哌嗪环状脲
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ripk1抑制劑之異㗁唑啶及其用途
US12459909B2 (en) 2020-06-18 2025-11-04 The Regents Of The University Of California Nitrosation reagents and methods
EP4308555A4 (en) * 2021-03-18 2025-07-30 Sironax Ltd RECEPTOR-INTERACTING PROTEIN-1 INHIBITORS, PREPARATIONS AND USES THEREOF
CA3218159A1 (en) 2021-05-20 2022-11-24 Zhaolan ZHANG Rip1 modulators including azetidine cyclic ureas, preparations, and uses thereof
WO2023083847A1 (en) 2021-11-11 2023-05-19 Sanofi Isoxazolidines as ripk1 inhibitors and use thereof
IL314082A (en) 2022-01-12 2024-09-01 Denali Therapeutics Inc Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756394B1 (en) 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
SI2384753T1 (sl) 2003-08-29 2016-06-30 The Brigham And Women's Hospital, Inc. Hidantoinski derivati kot inhibitorji celične nekroze
HUP0500921A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
EP1968583A4 (en) * 2005-12-20 2010-09-15 Harvard College COMPOUNDS, SCREENING AND TREATMENT PROCEDURES
US20090099242A1 (en) 2007-08-15 2009-04-16 Cuny Gregory D Heterocyclic inhibitors of necroptosis
AU2008327106B2 (en) * 2007-11-20 2012-10-04 Sumitomo Chemical Company, Limited Pyridine compound, pesticidal composition and method of controlling pest
JP2010100611A (ja) * 2008-09-26 2010-05-06 Sumitomo Chemical Co Ltd ピリジン化合物及びその有害生物の防除用途
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
CA2772760A1 (en) * 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP2012041325A (ja) * 2010-08-23 2012-03-01 Bayer Cropscience Ag オキサジアゾリノン誘導体およびその有害生物の防除用途
WO2012125544A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
US8889730B2 (en) * 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP5532078B2 (ja) 2012-05-23 2014-06-25 株式会社デンソー 乗員保護装置
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺

Similar Documents

Publication Publication Date Title
JP2018504393A5 (https=)
JP2018502101A5 (https=)
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2526201C2 (ru) Способ лечения артрита
JP2007519649A5 (https=)
JP2018502877A5 (https=)
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
RU2010106854A (ru) Производные 2-аза-бицикло[3.3.0]октана
JP2006507326A5 (https=)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
JP2016509591A5 (https=)
BR112015010063A2 (pt) método para o tratamento ou prevenção de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, utilização de um composto de fórmula (i), um derivado da colquicina conhecido e/ou um sal do mesmo, composição para a prevenção ou tratamento de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, método e regime para reduzir ou prevenir a inflamação induzida por cristal de colesterol no interior das placas ateroscleróticas em um sujeito, regime para o tratamento ou prevenção de um acidente cardiovascular em um indivíduo
JP2010534647A5 (https=)
JP2014502979A5 (https=)
JP2018524390A5 (https=)
JP2017527578A5 (https=)
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
JP2019517587A5 (https=)
JP2016534124A5 (https=)
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2017518360A5 (https=)
DK1786790T3 (da) Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
RU2014144951A (ru) Новое 1-замещенное производное индазола